Purpose {#sec1}
=======

Brachytherapy, owing to the close apposition between the target and the radiation source, is undoubtedly the radiotherapeutic technique that offers maximum conformality. Ultrasound (USG) makes use of the different echogenicity between different tissues, and serves as an effective tool for delineating tumors and differentiates them from surrounding normal tissues. Ultrasonography is attractive as an image guidance modality in brachytherapy, since it is portable, inexpensive, and simple to use, and thus allows for accurate, conformal, reproducible, and adaptive treatments. The newer planning systems for brachytherapy utilize USG as the sole modality for imaging. An imaging based brachytherapy procedure can be divided into four different steps: 1) image-assisted provisional treatment planning, 2) image-guided application, 3) image-assisted definitive treatment planning, 4) image-assisted quality control. European Society for Radiotherapy and Oncology (ESTRO) has recognized USG as a valuable tool for the first 3 steps \[[@cit0001]\]. Considering the widespread use of USG in prostate cancer brachytherapy and its increasing role in gynecological and breast cancer brachytherapy, we decided to explore the current status of its use in brachytherapy in all sites, recent advances, and future possibilities.

Material and methods {#sec2}
====================

English language literature (till November 2016), illustrating the use of USG for brachytherapy, was queried for the following terms: 'brachytherapy', 'high-dose-rate', 'ultrasound', '3-dimensional ultrasound', 'image guidance', 'planning for individual sites of cancer'. The available evidences were summarized, including indications from more widespread and routine use in clinical practice to less common sites. The focus was not to give a systematic review, but to include studies that help sensitize the reader about varied uses and development of USG for brachytherapy in different sites.

Ultrasonography imaging in prostate brachytherapy {#sec2.1}
-------------------------------------------------

In the 1980s, the use of transperineal needles and transrectal USG (TRUS) guidance brought attention to brachytherapy for prostate cancer \[[@cit0002]\]. The use of USG gathered momentum with its widespread use in low-dose-rate (LDR) pre-planning, LDR seed insertion, and high-dose-rate (HDR) needle or catheter insertion. With continual development, USG overtook all imaging modalities through all steps of prostate brachytherapy. After HDR brachytherapy has shown equivalent clinical results to LDR brachytherapy, it has gained ever increasing popularity with lesser number of high-dose fractions. Concurrently, the need to accurately deliver the planned treatment with minimal catheter displacement has also arisen. Evolution of TRUS and the availability of sophisticated treatment planning computers have evolved into a reliable system of treating prostate cancer patients by brachytherapy, either in form of boost or monotherapy. A technical note by Morton argues in favor of TRUS-based planning with delivery of a single HDR fraction as an effective and well-tolerated tool for local dose escalation for patients with intermediate and high-risk disease \[[@cit0003]\]. A TRUS-guided HDR prostate procedure is easy to perform and convenient for the patient. The procedure takes about 90 minutes and the patient is treated without any displacement. Identifying the catheters is not difficult, and a number of USG base planning systems are now commercially available. Early results (median follow-up of 10 months) of use of HDR single fraction boost brachytherapy with use of USG only for positioning and planning have been published by Oliver *et al.*, with dose planning objectives reached in 90% cases, with none reporting more than grade 2 toxicity, early recovery of baseline urinary function, and promising PSA responses \[[@cit0004]\]. Recent advances in the field of contrast-enhanced USG seems to be promising for intraprostatic lesion localization as a support for brachytherapy treatment planning. Dose coverage in the intraprostatic lesion could be improved without increasing a dose to organs at risk \[[@cit0005]\].

Ultrasonography imaging in gynecologic brachytherapy {#sec2.2}
----------------------------------------------------

Use of USG for gynecologic brachytherapy dates back to the 1970s \[[@cit0006]\]. The use of real time trans-abdominal ultrasound (TAUS) or TRUS, increases the probability and safety of accurate placement of the uterine tandem. Trans-abdominal ultrasound performed during an insertion of uterine tandem and ovoids, allows accurate 3D measurement of uterine wall thickness at multiple anatomical levels \[[@cit0007]\]. This information can be used in conjunction with orthogonal radiographs in order to calculate bladder base doses, and allows real-time assessment of surrounding visceral doses. Ultrasonography has been successfully used for planning in the intracavitary applications incorporating all these advantages \[[@cit0008], [@cit0009]\].

One of the first reported uses of USG for interstitial gynecologic brachytherapy was by Stock *et al.* who demonstrated the usefulness of USG to visualize the target as well as normal tissues in 12 patients \[[@cit0010]\]. Sharma *et al.* reported on their experience using TRUS to assist with needle placement in 40 procedures in 25 patients, avoiding any bladder or rectal perforations \[[@cit0011]\]. Other groups have also reported their experience using USG to assist the guidance of brachytherapy catheters with each demonstrating feasibility and safety in a prospective setting. Investigators from Mumbai have shown a reasonable correlation between TAUS and MRI-based (magnetic resonance imaging) planning \[[@cit0012]\]. The Melbourne group has used USG as the sole modality for positioning and planning in intracavitary treatment of cancer cervix. Encouraging clinical results in a large cohort of cervical cancer patients (292 patients, non-stage IV) have been reported with a median follow-up period of 4.1 years, a five-year local control of 87.5%, and acceptable toxicity profile. The 5-year failure-free survival and overall survival were 66% and 65%, respectively \[[@cit0008]\].

Mitchell *et al.* have described USG based gynecologic planning to be a "2.5-dimensional" approach in the sense that the USG measurements are used to inform the planning, however the prescription is not based on a 3-dimensional volume \[[@cit0013]\]. Currently, USG cannot be used as a planning tool for complicated interstitial brachytherapy. It can be used to place the needles and delineate the Groupe Européen de Curiethérapie European Society for Radiotherapy and Oncology (GEC-ESTRO) defined high-risk clinical target volume (HR-CTV). The Vienna group suggests that delineating of HR-CTV from TRUS may soon be an acceptable modality \[[@cit0014]\]. A recent proof of concept has been enunciated for use of trans-cervical endosonography (TRACE) in pre-planning, real-time guidance, and treatment planning of cervical cancer image-guided adaptive brachytherapy (IGABT), and can serve as an interesting addition to complement existing imaging technologies \[[@cit0015]\].

Ultrasonography imaging in breast brachytherapy {#sec2.3}
-----------------------------------------------

Interstitial brachytherapy-based accelerated partial breast irradiation (APBI) is a relatively recent development in breast radiotherapy that has gained international favor, with recent evidences suggesting that HDR APBI is here to stay \[[@cit0016]\]. Interstitial brachytherapy has also been used as a boost therapy after whole breast external beam radiotherapy (EBRT). The first use of USG for APBI was described as early as 1997, and it has now become the most ubiquitous modality used for postoperative applicator placement \[[@cit0017], [@cit0018]\]. When the applicator is placed in the operating room, USG can also confirm applicator positioning and the lack of air within the lumpectomy cavity \[[@cit0019]\]. Using three-dimensional ultrasound (3D-USG) to image the patient in breast brachytherapy can be effective as a primary treatment planning imaging modality in breast cancer. The images collected with the applicator in situ can provide a means of optimizing the dose delivered, sparing adjacent normal structures along with a fast and efficient way of delivering personalized real-time guidance, and planning for breast HDR brachytherapy treatments \[[@cit0020], [@cit0021]\].

Ultrasonography imaging in anal cancer brachytherapy {#sec2.4}
----------------------------------------------------

3D endoluminal USG has gained popularity in assessment and interventions for luminal structures such as esophagus and rectum/anal canal. A few centers have extended this application for guiding brachytherapy procedures in anal canal, with the advantages of optimizing implant procedure and better information for dose planning, akin to prostate cancer interstitial brachytherapy. By using an anal obturator or dilator, the dose to the healthy side of the anal canal is limited. Under USG control, the needles are implanted directly into the tumor or tumor bed, and real-time treatment planning is possible. Imaging allows for control of the dose distribution and ensures that the whole tumor is covered by the reference isodose \[[@cit0022], [@cit0023]\]. Kiel *et al.* have described their long term clinical experience with this technique in 104 patients with a 10-year mean follow-up period, showing a local control of 89% and overall survival of 93% \[[@cit0024]\].

Lung brachytherapy {#sec2.5}
------------------

Interstitial brachytherapy has shown promising results for inoperable peripheral lung tumors in terms of safety and efficacy in limited reports, and could potentially be an approach for selected curative treatments, as well as an alternative to radiofrequency ablation, sparing major damage to radiosensitive surrounding structures. In a pilot study reported by Harms *et al.*, inoperable peripheral malignant lung lesions were approached by electromagnetic navigation and the position was confirmed by endobronchial USG \[[@cit0025]\].

Brachytherapy for abdominal wall metastases {#sec2.6}
-------------------------------------------

Kishi *et al.* have reported on the use of interstitial brachytherapy for treatment of subcutaneous metastatic abdominal wall tumors. They developed a technique utilizing USG-guided insertion of applicator needles to avoid the organs at risk such as intestines, and saline injection into the subcutaneous tissue between the tumor and the skin to decrease the skin dose. Single dose of 20 Gy was administered. Long-lasting pain reduction and tumor shrinkage was obtained without significant early or late complications \[[@cit0026]\].

Extrahepatic bile duct intraluminal brachytherapy {#sec2.7}
-------------------------------------------------

Intraluminal brachytherapy with a transcatheter Iridium-192 (^192^Ir) wire, as a method to deliver a boost to patients with tumors of extrahepatic bile ducts, has been sufficiently discussed in published series. A major limitation of current imaging techniques is the inability to accurately define the proximal, distal, and most importantly, the lateral extent of tumor. Minsky *et al.* were able to utilize the advantage of small diameters of endoluminal USG probes allowing insertion into a biliary duct drainage tube and used it to successfully determine tumor volume in the bile ducts \[[@cit0027]\].

Brachytherapy of head and neck tumors {#sec2.8}
-------------------------------------

Literature on use of USG for head and neck brachytherapy is relatively sparse, but it can be a valuable companion in locally-advanced primary cancers, as well as in recurrent head and neck cancers. Needles can be positioned under continuous USG guidance, and adjacent structures (e.g. the carotid artery) are easily localized, thus avoiding violation of large vessels and optimizing exact positioning of needles within the tumor \[[@cit0028]\].

Discussion {#sec3}
==========

Most technical arguments against the use of brachytherapy list the possibility of needle displacement from the time of insertion to the time of treatment, difficulty in delineation of tumor due to artefacts from metallic needles in computed tomography (CT)-based planning, and fear of violating major vessels in the vicinity of tumor. Use of CT-compatible needles as well as magnetic resonance imaging (MRI) based planning have been able to avoid the problem of CT artefacts. However, associated increased cost, and limited availability and training requirements are issues that pose hindrances.

In the era of intensity modulated radiotherapy and stereotactic body radiotherapy, brachytherapy needs to prove itself as a worthy competitor or alternative to external beam radiotherapy for delivering high fractional dose for radical or boost treatments. This is achievable when employing modern imaging tools for guidance and navigation for brachytherapy implantation, as well as for treatment planning and delivery in the same position. This allows to deliver a high dose inside the tumor, sparing surrounding critical structures with zero geometric uncertainty. The American Association of Physicists in Medicine Task Group 43 (AAPM TG-43) dose calculation formalism for photon-emitting radionuclide sources is the mainstay of brachytherapy dosimetry in clinical practice. The TG-43 adopted universally, provides a standardized method to brachytherapy dose calculation based on the superposition of single-source dosimetry in water medium and is simple to use.

The establishment of brachytherapy as the treatment of choice for early organ-confined prostate cancer, where USG imaging for pre- and intraoperative planning and needle insertion along with CT based planning, led to developments in the field of imaging-based brachytherapy treatment planning. This has also translated into similar advances for other sites as well. Conventional USG has been widely used in brachytherapy, mainly to guide needle placement and is useful in planning when combined with other modalities. Two-dimensional viewing of 3-dimensional structures, using conventional USG, limits ability to quantify and visualize the anatomy and guide therapy. It needs multiple 2-dimensional images to be integrated mentally, and increased the possibility of inter-observer variability and inaccuracy \[[@cit0029]\]. The newer developments in USG such as 3D USG, contrast-enhanced USG, and high frequency USG have been introduced with success in diagnostic, interventional, and therapeutic fields. The 3D USG system gives a spatially oriented and standardized view, thereby reducing operator dependence and improving reproducibility. It gives an accurate 3D anatomical display and is valuable in carrying interventional procedures by using multiplanar views \[[@cit0029]\]. In 3D USG imaging, the inter-plane distance can be as low as 1.0 mm, resulting in accuracy better than 1.0 mm (\~ 0.5 mm) for catheter reconstruction. Other benefit of USG imaging for the reconstruction of catheters is the possibility to combine 3D volume reconstruction with live 2D imaging \[[@cit0030]\]. The United States Food and Drug Administration (US FDA) has not approved a microbubble agent for radiology imaging, but ultrasound contrast agents (UCAs) are popular and widely used in Europe and Asia \[[@cit0031]\]. Use of contrast-enhanced ultrasound is cost-effective, can be performed at bedside, uses no ionizing radiation, has no nephrotoxicity, and can provide diagnostic information comparable to CT and MRI \[[@cit0031]\].

With the expanding use and availability of USG, the impression that USG is a subjective assessment may not hold true in the near future. A study focusing on training Indian surgery residents in use of abdominal USG for 2 months showed that it was not difficult to learn with achievement of similar proficiency as that of a radiology resident following the training \[[@cit0032]\]. Studies from USA have reported on increasing utilization of USG by anesthetists for regional block procedures, and its use has rapidly entered the field of acute pain medicine and regional anesthesia and interventional pain medicine over the last decade, raring to become the standard of practice in due course of time \[[@cit0033]\]. Ultrasonography training may become progressively easier with reducing cost of machines as well as ease of preparation of low cost phantoms for USG \[[@cit0034]\]. A summary of the authors' understanding comparing CT, MR and USG has been tabulated in [Table 1](#t0001){ref-type="table"}.

###### 

Computed tomography, magnetic resonance imaging and ultrasonography in image-guided brachytherapy (authors' recommendations)

  Imaging modality   Soft tissue imaging   Guided catheter/application           Availability                     Cost       Applicators             Catheter reconstruction
  ------------------ --------------------- ------------------------------------- -------------------------------- ---------- ----------------------- -------------------------
  CT                 Good                  Useful, limited by radiation hazard   Commonly available               Moderate   Cheap, cause artefact   Good
  MRI                Excellent             Useful, limited by availability       Uncommonly available             High       Costly, fragile         Good
  USG                Good to excellent     Useful, artifacts can pose problems   Can be made commonly available   Low        Cheap                   Good

CT -- computed tomography, MRI -- magnetic resonance imaging, USG -- ultrasonography

Limitations {#sec4}
===========

Morton has pointed on several limitations of the use of USG in prostate brachytherapy, and these apply equally to other sites as well. It needs a shielded operating room or the ability to deliver anesthesia in an HDR bunker. As image quality can be degraded by calcification, bleeding, or the shadowing effects of implanted catheters, it is important to get high-quality USG images. Ultrasonography is prone to distortion, sensitive to the temperature, and constitution of the medium, therefore requiring regular calibration. Radiation oncologists are unfamiliar with using USG, hence training for the same should be introduced to increase the confidence level of future doctors. The TRUS probe itself may cause a decreasing space between the vaginal wall or prostate and anterior rectal wall, with a possibility of higher dose in the contact region, and appropriate precautions need to be taken to get around this possibility. In gynecologic brachytherapy, we can try to use real-time guidance to create space between the posterior vaginal wall and anterior rectum. This can improve the potential therapeutic ratio of brachytherapy \[[@cit0013]\].

Clinical data using 3-dimensional USG in gynecological cancer and its use as a sole modality for volumetric treatment planning in cervical cancer are limited, due to poorer reproducibility and sub-optimal visualization of critical structures \[[@cit0035]\]. High-dose-rate prostate brachytherapy has circumvented some of these challenges, however further work is clearly needed especially for cervix and other sites. Considering the benchmark that USG has attained in prostate brachytherapy and accepting that most of the limitations are technical, scientific advancements in appropriate directions will hopefully solve the issues.

Conclusions {#sec5}
===========

Ultimately, the ideal treatment process following USG-based catheter insertion would be to perform real-time USG planning and delivery. Recent advancements in USG imaging and planning software of brachytherapy will help us obtain a real-time guidance, and estimate the dose delivery to the insertion position with zero geometric uncertainty. There are some limitations, which need to be addressed.

Dr Susovan Banerjee was deeply influenced by use of USG in prostate cancer brachytherapy by Dr. Gerard Morton, Sunnybrook Cancer Hospitals, Toronto, during educational visit in January 2016.
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